DK1676848T3 - Polymorfe former af rifaximin som antibiotika - Google Patents

Polymorfe former af rifaximin som antibiotika

Info

Publication number
DK1676848T3
DK1676848T3 DK06004220T DK06004220T DK1676848T3 DK 1676848 T3 DK1676848 T3 DK 1676848T3 DK 06004220 T DK06004220 T DK 06004220T DK 06004220 T DK06004220 T DK 06004220T DK 1676848 T3 DK1676848 T3 DK 1676848T3
Authority
DK
Denmark
Prior art keywords
rifaximin
antibiotics
polymorphic forms
polymorphic
forms
Prior art date
Application number
DK06004220T
Other languages
Danish (da)
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1676848(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK1676848T3 publication Critical patent/DK1676848T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK06004220T 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika DK1676848T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
DK1676848T3 true DK1676848T3 (da) 2009-05-11

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06004219T DK1676847T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK06004219T DK1676847T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum

Country Status (38)

Country Link
US (5) US7045620B2 (fr)
EP (6) EP1676847B1 (fr)
JP (5) JP2005139161A (fr)
KR (4) KR20050043589A (fr)
CN (4) CN1613858A (fr)
AR (3) AR043547A1 (fr)
AT (3) ATE421966T1 (fr)
AU (2) AU2004200964A1 (fr)
BR (2) BRPI0402382A (fr)
CA (2) CA2460384A1 (fr)
CL (1) CL2004000498A1 (fr)
CO (1) CO5560083A1 (fr)
CY (3) CY1108017T1 (fr)
DE (4) DE04005541T1 (fr)
DK (3) DK1676847T3 (fr)
ES (3) ES2244364T3 (fr)
HK (3) HK1092151A1 (fr)
HR (2) HRP20040265A2 (fr)
IL (2) IL160798A0 (fr)
IT (1) ITMI20032144A1 (fr)
JO (1) JO2470B1 (fr)
MA (1) MA27069A1 (fr)
MD (1) MD3653G8 (fr)
ME (1) ME00424B (fr)
MX (2) MXPA04002353A (fr)
NO (1) NO334950B1 (fr)
NZ (1) NZ531622A (fr)
PL (3) PL1557421T3 (fr)
PT (3) PT1676847E (fr)
RS (4) RS54568B1 (fr)
RU (1) RU2270200C2 (fr)
SI (3) SI1557421T1 (fr)
TN (2) TNSN04044A1 (fr)
TW (1) TWI285107B (fr)
UA (1) UA86384C2 (fr)
WO (1) WO2005044823A2 (fr)
YU (1) YU24804A (fr)
ZA (1) ZA200401948B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK2054066T3 (en) 2006-08-02 2015-06-08 Salix Pharmaceuticals Inc METHODS OF TREATMENT OF RADIATE ENTERITIS
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2007298733B2 (en) * 2006-09-22 2012-11-08 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (fr) * 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques de rifaximine
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
NZ587099A (en) * 2008-02-25 2012-08-31 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
MX2010009197A (es) 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
PT2294012E (pt) 2008-05-07 2014-10-15 Salix Pharmaceuticals Ltd Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2010040020A1 (fr) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Méthodes de traitement d’une encéphalopathie hépatique
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
BRPI1010028A2 (pt) * 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
CN102665693A (zh) * 2009-10-27 2012-09-12 鲁平有限公司 利福昔明固体分散体
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
EP2401282B2 (fr) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Procédés pour la production de rifaximine amorphe
EP3650022A1 (fr) 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Procédés pour traiter les infections par clostridium difficilis resistantes a la rifampine
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
SG10201507035UA (en) * 2010-06-03 2015-10-29 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
WO2012009387A1 (fr) * 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations de rifaximine et utilisations correspondantes
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (fr) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Procédé de préparation de rifaximine amorphe
WO2012076832A1 (fr) * 2010-12-09 2012-06-14 Cipla Limited Suppositoires contenant de la rifaximine
EA201391171A1 (ru) 2011-02-11 2014-11-28 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (fr) 2011-05-19 2012-11-22 Friulchem Spa Nouveau procédé pour la synthèse de rifaximine et nouvelle forme pseudo-cristalline de rifaximine obtenue au moyen de celui-ci
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
MX2015011802A (es) 2013-03-15 2016-01-08 Alfa Wassermann Spa Rifaximina para usarse en el tratamiento de infecciones vaginales.
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和***
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (fr) 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
CA2946101A1 (fr) * 2014-04-19 2015-10-22 Granules India Limited Procede ameliore pour la preparation de derives de la rifamycine
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (fr) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification de bactérie vaginale
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (fr) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Procédé de préparation de formes cristallines de rifaximine
ES2738024T5 (es) 2016-03-24 2022-10-24 Sandoz Ag Composición estable al almacenamiento que comprende rifaximina alfa
PL3294270T3 (pl) 2016-03-24 2019-02-28 Sandoz Ag Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
MX2018010065A (es) 2017-04-26 2019-02-07 Sandoz Ag Forma de dosificacion oral que comprende rifaximina en forma beta.
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny
WO2020245214A1 (fr) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Utilisation de méthylnaltrexone et de rifaximine pour le traitement d'une perméabilité intestinale accrue ou de troubles associés
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (fr) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorphe de la rifaximine, son procédé de préparation et composition pharmaceutique contenant de la rifaximine
EP4171520A1 (fr) 2020-06-26 2023-05-03 Bausch Health Ireland Limited Compositions de rifaximine à libération ciblée
WO2022090490A1 (fr) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (fr) 1984-05-15 1986-12-30 Vincenzo Cannata Nouvelle methode pour la synthese d'imidazorifamycines
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ATE125541T1 (de) * 1990-06-29 1995-08-15 Lepetit Spa Reine kristalline form von rifapentin.
CA2396079A1 (fr) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100338028C (zh) * 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
AU2007298733B2 (en) 2006-09-22 2012-11-08 Cipla Limited Rifaximin
WO2008115572A1 (fr) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Procédés et compositions d'ains
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (fr) 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques de rifaximine
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
NZ587099A (en) 2008-02-25 2012-08-31 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
EP1557421A1 (fr) 2005-07-27
CN101260114A (zh) 2008-09-10
DE602004019296D1 (de) 2009-03-19
CN101260115A (zh) 2008-09-10
BRPI0402382A (pt) 2005-06-28
RS54569B1 (en) 2016-06-30
JP2011057698A (ja) 2011-03-24
ATE361927T1 (de) 2007-06-15
ATE421966T1 (de) 2009-02-15
YU24804A (sh) 2006-08-17
TNSN04044A1 (en) 2006-06-01
DK1676847T3 (da) 2009-05-11
CN101260115B (zh) 2011-11-23
ES2244364T1 (es) 2005-12-16
CA2460384A1 (fr) 2005-05-07
JP5635376B2 (ja) 2014-12-03
AR081991A2 (es) 2012-10-31
BRPI0407149A8 (pt) 2019-01-15
US7045620B2 (en) 2006-05-16
RS54571B1 (en) 2016-06-30
HRP20060093B1 (hr) 2015-12-18
DE602004006367D1 (de) 2007-06-21
RS54568B1 (en) 2016-06-30
NZ531622A (en) 2004-10-29
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (fr) 2005-10-27
RS20150292A1 (en) 2015-10-30
EP1557421B1 (fr) 2007-05-09
PL1557421T3 (pl) 2007-08-31
HRP20060093A2 (en) 2006-05-31
ITMI20032144A1 (it) 2005-05-08
KR20060110737A (ko) 2006-10-25
AU2004200964A1 (en) 2005-05-26
MA27069A1 (fr) 2004-12-20
RU2270200C2 (ru) 2006-02-20
DE602004006367T2 (de) 2007-09-06
PL1676847T3 (pl) 2009-07-31
DE04005541T1 (de) 2005-12-29
WO2005044823A2 (fr) 2005-05-19
KR100867751B1 (ko) 2008-11-10
US20110160449A1 (en) 2011-06-30
NO334950B1 (no) 2014-08-04
SI1676847T1 (sl) 2009-06-30
US8173801B2 (en) 2012-05-08
EP2210893A1 (fr) 2010-07-28
SI1676848T1 (sl) 2009-06-30
CN1613858A (zh) 2005-05-11
US20050272754A1 (en) 2005-12-08
RU2004108953A (ru) 2005-10-27
JP2005139161A (ja) 2005-06-02
AU2004287601B8 (en) 2009-03-05
MXPA06002644A (es) 2006-06-06
HK1073657A1 (en) 2005-10-14
DE602004006367C5 (de) 2019-04-04
UA86384C2 (uk) 2009-04-27
CO5560083A1 (es) 2005-09-30
EP1682556A2 (fr) 2006-07-26
CA2538546C (fr) 2011-04-19
RS20150291A1 (en) 2015-10-30
IL174271A0 (en) 2006-08-01
DK1557421T3 (da) 2007-09-17
JO2470B1 (en) 2009-01-20
PT1676847E (pt) 2009-04-09
MXPA04002353A (es) 2005-05-11
RS20060168A (en) 2008-09-29
SI1557421T1 (sl) 2007-08-31
BRPI0407149A (pt) 2006-02-07
ZA200401948B (en) 2004-04-29
ATE421965T1 (de) 2009-02-15
ES2244364T3 (es) 2007-12-01
ES2320161T3 (es) 2009-05-19
KR20070113327A (ko) 2007-11-28
NO20061110L (no) 2006-04-19
CN1886408A (zh) 2006-12-27
KR100855084B1 (ko) 2008-08-29
JP2007509904A (ja) 2007-04-19
DE602004019298D1 (de) 2009-03-19
US20050101598A1 (en) 2005-05-12
TW200515913A (en) 2005-05-16
EP1676847A1 (fr) 2006-07-05
CN101260114B (zh) 2012-11-28
CL2004000498A1 (es) 2005-03-11
AU2004287601A1 (en) 2005-05-19
HK1092150A1 (en) 2007-02-02
JP2014177500A (ja) 2014-09-25
EP1676848A1 (fr) 2006-07-05
US7915275B2 (en) 2011-03-29
PT1676848E (pt) 2009-04-09
EP2208730A1 (fr) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
US20120059023A1 (en) 2012-03-08
EP1676848B1 (fr) 2009-01-28
MD3653G8 (ro) 2016-08-31
KR100883216B1 (ko) 2009-02-13
CN1886408B (zh) 2010-06-09
HK1092151A1 (en) 2007-02-02
CY1108017T1 (el) 2013-09-04
PT1557421E (pt) 2007-07-31
CA2538546A1 (fr) 2005-05-19
EP1676847B1 (fr) 2009-01-28
US20080132530A1 (en) 2008-06-05
MD3653F2 (en) 2008-07-31
AR081992A2 (es) 2012-10-31
TWI285107B (en) 2007-08-11
IL160798A0 (en) 2004-08-31
ME00424B (fr) 2011-10-10
KR20070113326A (ko) 2007-11-28
TNSN06069A1 (en) 2007-10-03
AR043547A1 (es) 2005-08-03
KR20050043589A (ko) 2005-05-11
JP2011046738A (ja) 2011-03-10
US8404704B2 (en) 2013-03-26
AU2004287601B2 (en) 2009-02-26
IL174271A (en) 2010-12-30
MD20060080A (en) 2006-11-30
ES2320160T4 (es) 2011-03-09
CY1108964T1 (el) 2014-07-02
JP5199576B2 (ja) 2013-05-15
CY1108909T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
DK1676848T3 (da) Polymorfe former af rifaximin som antibiotika
SE0301569D0 (sv) Novel compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
IS8228A (is) Ný asetídínefnasambönd
IS8089A (is) Efnasambönd
DE602004018602D1 (de) Mikrospiegel
IS8292A (is) Ný efnasambönd
ATE463248T1 (de) Cephem-verbindungen
FI20030030A0 (fi) Uusia yhdisteitä
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
DE602004028552D1 (de) Nockenwellenversteller
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
SE0302667D0 (sv) Novel Compounds
SE0301120D0 (sv) New compounds
SE0302368D0 (sv) New compounds
SE0303181D0 (sv) New compounds
SE0303078D0 (sv) New compounds
SE0302369D0 (sv) New compounds